Table 2.
Baseline characteristics of studies evaluating the association between CGM-derived TIR and microvascular complications among type 2 diabetes [18]
| Characteristics | All included studies (n = 11) | TIR and diabetic retinopathy (n = 4) | TIR and diabetic nephropathy (n = 4) | TIR and diabetic neuropathy (n = 7) |
|---|---|---|---|---|
| Sample size, n (range) | 466 (105–5901) | 2315.5 (281–5901) | 932.5 (281–5901) | 349 (105–740) |
| Sex (%) | ||||
| Male | 60.8 | 58.1 | 62.0 | 62.6 |
| Female | 39.2 | 41.9 | 38.0 | 37.4 |
| Age, years, mean (SD) | 59.3 (1.3) | 62.1 (0.99) | 61.6 (0.4) | 59.1 (2.8) |
| Baseline A1c, %, mean (SD) | 8.2 (0.5) | 8.0 (0.6) | 7.8 (0.4) | 8.1 (0.6) |
| Duration of diabetes, years, mean (SD) | 11.3 (1.0) | 11.8 (0.7) | 13.1 (0.2) | 11.0 (1.1) |
| Study location (n) | ||||
| China | 5 | |||
| South Korea | 2 | |||
| Japan | 2 | |||
| India | 1 | |||
| USA | 1 | |||
| CGM device used (n) | ||||
| Medtronic | 5 | |||
| Abbott FreeStyle Libre | 4 | |||
| Meiqi | 1 | |||
| Medtronic + Meiqi | 1 | |||
| Duration of CGM use (n) | ||||
| 3 days | 4 | |||
| 14 days | 4 | |||
| 3 and 6 days for GOLD (Medtronic) and iPro2 (Medtronic), respectively‡ | 2 | |||
| Two 6-day periods, separated by 2 weeks | 1 | |||
| CGM device calibrations (n) | ||||
| Not applicable | 4 | |||
| At least two times per day | 3 | |||
| At least four times per day | 3 | |||
| Not reported | 1 | |||